WAYNE, Pa.--(BUSINESS WIRE)--The enormous global problem of tuberculosis (with roughly one-third of the world’s population infected with Mycobacterium tuberculosis), coupled with an increasing incidence of infections caused by nontuberculous mycobacteria, present unique challenges for the laboratory diagnosis of mycobacterial infections. The diagnosis of M. tuberculosis needs to be optimized and expedited for good patient management and appropriate control measures need to be implemented to prevent transmission of tuberculosis. There are similar demands for accurate identification of the ever-increasing numbers of species of nontuberculous mycobacteria.
In light of these issues, Clinical and Laboratory Standards Institute (CLSI) has recently published Laboratory Detection and Identification of Mycobacteria; Approved Guideline (M48-A). The document addresses the following topics:
As a practical working document, this guideline is intended to provide recommendations to laboratories on the total testing process for patients with suspected mycobacterial infections. Although the document’s primary focus is on the diagnosis of M. tuberculosis infections, nontuberculous mycobacteria are also addressed, both in terms of their clinical significance and in terms of optimal laboratory methods for direct detection, culture, and identification.
For additional information on CLSI or for further information regarding this release, visit the CLSI website at www.clsi.org or call +610.688.0100.
CLSI, formerly NCCLS, is a global, nonprofit, membership-based organization dedicated to developing standards and guidelines for the health care and medical testing community. CLSI’s unique consensus process facilitates the creation of standards and guidelines that are reliable, practical, and achievable for an effective quality system.